Antibodies capable of neutralizing HIV-1 often target variable regions 1 and 2 (V1V2) of the
HIV-1 envelope, but the mechanism of their elicitation has been unclear. Here we define the …

The elicitation of broadly neutralizing antibodies (bNAbs) is likely to be essential for a
preventative HIV-1 vaccine, but this has not yet been achieved by immunization. In contrast …

Current human immunodeficiency virus-1 (HIV-1) vaccines elicit strain-specific neutralizing
antibodies. However, cross-reactive neutralizing antibodies arise in approximately 20% of …

The epitopes defined by HIV-1 broadly neutralizing antibodies (bNAbs) are valuable
templates for vaccine design, and studies of the immunological development of these …

A major goal of HIV-1 vaccine research is the design of immunogens capable of inducing
broadly neutralizing antibodies (bnAbs) that bind to the viral envelope glycoprotein (Env) …

The events required for the induction of broad neutralizing antibodies (bnAbs) following HIV-
1 envelope (Env) vaccination are unknown, and their induction in animal models as proof of …

Over the past 5 years, a new generation of highly potent and broadly neutralizing HIV-1
antibodies has been identified. These antibodies can protect against lentiviral infection in …

Antibodies of the VRC01 class neutralize HIV-1, arise in diverse HIV-1-infected donors, and
are potential templates for an effective HIV-1 vaccine. However, the stochastic processes …

The design of immunogens that elicit broadly reactive neutralizing antibodies (bnAbs) has
been a major obstacle to HIV-1 vaccine development. One approach to assess potential …

ABSTRACT V2/V3 conformational epitope antibodies that broadly neutralize HIV-1 (PG9
and PG16) have been recently described. Since an elicitation of previously known broadly …